Foundation for Adenosine Research
EIN 39-4648664 • Charlottesville, VA
Pub. 78 Eligible
Profile
To advance scientific understanding and innovation in the field of adenosine biology by supporting the exploration of adenosine's role in human health and disease, fostering collaboration across disciplines, and accelerating discoveries into transformative therapies for the benefit of patients and society, as well as the making of distributions to organizations that qualify as exempt organizations under the Internal Revenue Code.
Siviq Scores
Scores are not available for this record yet.
Balance Sheet
Assets
$29,345
No earlier filing loaded for comparison.
Liabilities
$0
No earlier filing loaded for comparison.
Net Assets
$29,345
No earlier filing loaded for comparison.
Operations
Revenue
$75,000
No earlier filing loaded for comparison.
Expenses
$45,655
No earlier filing loaded for comparison.
Net Income
$29,345
No earlier filing loaded for comparison.
Trend Graphs
Filings
Most recent year
2025 • Form 990EZDetailed filing. Detailed filing data is available for this year.
- Assets
- $29,345
- Liabilities
- $0
- Net assets
- $29,345
- Revenue
- $75,000
- Expenses
- $45,655
- Net income
- $29,345
Latest Filing Detail
Jump To
Filing Snapshot
- Filing Period
- Oct 1, 2025 to Dec 31, 2025
- Signed
- May 18, 2026
- Return Version
- 2025v4.0
- Gross Receipts
- $75,000
Mission and Program Overview
Mission
To advance scientific understanding and innovation in the field of adenosine biology by supporting the exploration of adenosine's role in human health and disease, fostering collaboration across disciplines, and accelerating discoveries into transformative therapies for the benefit of patients and society, as well as the making of distributions to organizations that qualify as exempt organizations under the Internal Revenue Code.
Program Services
| Description | Grants | Expenses |
|---|---|---|
| Research Grantmaking and Scientific Program Support. 70 percent of total activity and 85-88 percent of expenses. FAR awards research grants and provides targeted financial support for early stage scientific investigations in adenosine biology. Grants are designed to support hypothesis-driven preclinical and translational research, including pilot studies, proof-of-concept experiments, and data generation necessary to advance understanding of adenosine signaling in areas such as oncology, autoimmune disease, inflammation, and metabolic disorders. Scientific review and funding recommendations are supported by external scientific advisors and, beginning in 2026, a formal Scientific Advisory Council composed of independent subject-matter experts who serve as unpaid volunteers. Funded research activities are conducted at third-party academic institutions, nonprofit research organizations, and qualified research laboratories in the US. FAR does not operate laboratory facilities. Activity is funded entirely through charitable donations. Expenses are allocable to research grants, pilot studies, and associated scientific program support. Activity directly furthers FAR's scientific and educational purposes by advancing basic and translational research related to adenosine biology. Funding early stage research reduces barriers to discovery, promotes dissemination of scientific knowledge, and accelerates progress toward therapies that benefit public health. | $42,500 | $0 |
| Governance, Compliance, and Organizational Operations. 10 percent of total activity and 5-10 percent of expenses. FAR maintains essential governance, compliance and administrative operations, including board management, financial oversight, regulatory filings, donor stewardship and organizational planning. Professional service providers (legal, accounting, insurance) are engaged as needed. Administrative activities are conducted remotely and through third-party service providers. Funded through charitable donations. Effective governance and compliance ensures FAR operates exclusively for charitable and scientific purposes and maintains accountability to donors and the public. | $0 | $3,155 |
| ACCORD (Adenosine Cancer Collaborative for Oncology Research and Discovery). 10 percent of total activity and 5-8 percent of expenses. FAR convenes and supports ACCORD, a structured scientific collaboration focused on the role of adenosine signaling in cancer biology and treatment. ACCORD facilitates coordinated data review, prioritization of research questions and alignment of preclinical research efforts across participating investigators. The activity includes invited academic researchers, clinicians and scientific advisors. ACCORD activities are conducted through virtual meetings and periodic in-person scientific convenings hosted at partner academic or research institutions. ACCORD is funded through charitable donations. Expenses are primarily for meeting coordination, scientific review support, and limited pilot study funding. By fostering collaboration and coordination among researchers, ACCORD enhances scientific efficiency, reduces duplication of effort, and promotes the generation and dissemination of new scientific knowledge related to cancer biology and treatment. | $0 | $0 |
| Scientific Advisory and Educational Convenings. 10 percent of total activity and 5-7 percent of expenses. FAR organizes scientific workshops, advisory meetings, and structured educational convenings to review emerging research, define research priorities and educate stakeholders on advances in adenosine biology. Convenings are focused on scientific exchange and strategic research planning. Activities include participation from volunteer scientific advisors, academic researchers, and clinicians. FAR's Scientific Advisory Council will participate on an unpaid, volunteer basis. Activities are conducted through virtual platforms and occasional in-person meetings hosted at academic or nonprofit venues. Funded through charitable donations. These activities further FAR's educational and scientific mission by promoting knowledge sharing, supporting informed research decision-making and advancing understanding of adenosine-related biology and disease mechanisms. | $0 | $0 |
Compensation and Service Providers
Employees
| Name | Title | Full / Part Time | Base | Other | Total |
|---|---|---|---|---|---|
| William Stilley | Director | - | $0 | - | - |
| J Kermit Anderson | Director | - | $0 | - | - |
| James Newman | Director | - | $0 | - | - |
| Uday Gupta | President & Treasurer | PT | $0 | - | - |
| John Martin | Secretary | - | $0 | - | - |
Filing and Contact Details
Filer
- Filer Name
- Foundation for Adenosine Research
- EIN
- 39-4648664
- Phone
- 4342260683
- Address
- 1180 Seminole Trail Ste 495, Charlottesville, VA 22901
Signing Officer
- Name
- Uday Gupta
- Title
- President & Treasurer
- Phone
- 4342423945
- Signed
- 2026-05-18
- Discuss with paid preparer
- Yes
Preparer
- Firm
- Shuru Law LLC
- Address
- 3334 Turnberry Circle, Charlottesville, VA 22911
- Preparer
- Rahul Keshap
- Phone
- 4342260683
Raw XML Appendix185 raw XML fields
This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.
| Path | # | Value |
|---|---|---|
| IRS990EZ/ActivitiesNotPreviouslyRptInd | 0 | 0 |
| IRS990EZ/ApplicationPendingInd | 0 | X |
| IRS990EZ/BenefitsPaidToOrForMembersAmt | 0 | 0 |
| IRS990EZ/BooksInCareOfDetail/PersonNm | 0 | Uday Gupta |
| IRS990EZ/BooksInCareOfDetail/PhoneNum | 0 | 4342423945 |
| IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt | 0 | 1180 Seminole Trail Ste 495 |
| IRS990EZ/BooksInCareOfDetail/USAddress/CityNm | 0 | Charlottesville |
| IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd | 0 | VA |
| IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd | 0 | 22901 |
| IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt | 0 | 0 |
| IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt | 0 | 29345 |
| IRS990EZ/ChgMadeToOrgnzngDocNotRptInd | 0 | 0 |
| IRS990EZ/ContributionsGiftsGrantsEtcAmt | 0 | 75000 |
| IRS990EZ/CostOfGoodsSoldAmt | 0 | 0 |
| IRS990EZ/CostOrOtherBasisExpenseSaleAmt | 0 | 0 |
| IRS990EZ/DirectIndirectPltclExpendAmt | 0 | 0 |
| IRS990EZ/DonorAdvisedFndsInd | 0 | 0 |
| IRS990EZ/EngagedInExcessBenefitTransInd | 0 | 0 |
| IRS990EZ/ExcessOrDeficitForYearAmt | 0 | 29345 |
| IRS990EZ/FeesAndOtherPymtToIndCntrctAmt | 0 | 3155 |
| IRS990EZ/FiledScheduleAInd | 0 | 1 |
| IRS990EZ/ForeignFinancialAccountInd | 0 | 0 |
| IRS990EZ/ForeignOfficeInd | 0 | 0 |
| IRS990EZ/Form1120PolFiledInd | 0 | 0 |
| IRS990EZ/Form990TotalAssetsGrp/BOYAmt | 0 | 0 |
| IRS990EZ/Form990TotalAssetsGrp/EOYAmt | 0 | 29345 |
| IRS990EZ/FundraisingGrossIncomeAmt | 0 | 0 |
| IRS990EZ/GainOrLossFromSaleOfAssetsAmt | 0 | 0 |
| IRS990EZ/GamingGrossIncomeAmt | 0 | 0 |
| IRS990EZ/GrantsAndSimilarAmountsPaidAmt | 0 | 42500 |
| IRS990EZ/GrossProfitLossSlsOfInvntryAmt | 0 | 0 |
| IRS990EZ/GrossReceiptsAmt | 0 | 75000 |
| IRS990EZ/GrossSalesOfInventoryAmt | 0 | 0 |
| IRS990EZ/InitialReturnInd | 0 | X |
| IRS990EZ/InvestmentIncomeAmt | 0 | 0 |
| IRS990EZ/LandAndBuildingsGrp/BOYAmt | 0 | 0 |
| IRS990EZ/LandAndBuildingsGrp/EOYAmt | 0 | 0 |
| IRS990EZ/LobbyingActivitiesInd | 0 | 0 |
| IRS990EZ/MadeLoansToFromOfficersInd | 0 | 0 |
| IRS990EZ/MembershipDuesAmt | 0 | 0 |
| IRS990EZ/MethodOfAccountingCashInd | 0 | X |
| IRS990EZ/NetAssetsOrFundBalancesBOYAmt | 0 | 0 |
| IRS990EZ/NetAssetsOrFundBalancesEOYAmt | 0 | 29345 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt | 0 | 0 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt | 0 | 29345 |
| IRS990EZ/OccupancyRentUtltsAndMaintAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 0 | 1 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 1 | 1 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 2 | 1 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 3 | 5 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 4 | 2 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 3 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 4 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 3 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 4 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 3 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 4 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 0 | William Stilley |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 1 | J Kermit Anderson |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 2 | James Newman |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 3 | Uday Gupta |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 4 | John Martin |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 0 | Director |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 1 | Director |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 2 | Director |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 3 | President & Treasurer |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 4 | Secretary |
| IRS990EZ/OperateHospitalInd | 0 | 0 |
| IRS990EZ/Organization501c3Ind | 0 | X |
| IRS990EZ/OrganizationDissolvedEtcInd | 0 | 0 |
| IRS990EZ/OrganizationHadUBIInd | 0 | 0 |
| IRS990EZ/OtherAssetsTotalDetail/BOYAmt | 0 | 0 |
| IRS990EZ/OtherAssetsTotalDetail/EOYAmt | 0 | 0 |
| IRS990EZ/OtherChangesInNetAssetsAmt | 0 | 0 |
| IRS990EZ/OtherExpensesTotalAmt | 0 | 0 |
| IRS990EZ/OtherRevenueTotalAmt | 0 | 0 |
| IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt | 0 | NONE |
| IRS990EZ/PartVIOfCompOfHghstPdEmplTxt | 0 | NONE |
| IRS990EZ/PoliticalCampaignActyInd | 0 | 0 |
| IRS990EZ/PrimaryExemptPurposeTxt | 0 | To advance scientific understanding and innovation in the field of adenosine biology by supporting the exploration of adenosine's role in human health and disease, fostering collaboration across disciplines, and accelerating discoveries into transformative therapies for the benefit of patients and society, as well as the making of distributions to organizations that qualify as exempt organizations under the Internal Revenue Code. |
| IRS990EZ/PrintingPublicationsPostageAmt | 0 | 0 |
| IRS990EZ/ProgramServiceRevenueAmt | 0 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 0 | Research Grantmaking and Scientific Program Support. 70 percent of total activity and 85-88 percent of expenses. FAR awards research grants and provides targeted financial support for early stage scientific investigations in adenosine biology. Grants are designed to support hypothesis-driven preclinical and translational research, including pilot studies, proof-of-concept experiments, and data generation necessary to advance understanding of adenosine signaling in areas such as oncology, autoimmune disease, inflammation, and metabolic disorders. Scientific review and funding recommendations are supported by external scientific advisors and, beginning in 2026, a formal Scientific Advisory Council composed of independent subject-matter experts who serve as unpaid volunteers. Funded research activities are conducted at third-party academic institutions, nonprofit research organizations, and qualified research laboratories in the US. FAR does not operate laboratory facilities. Activity is funded entirely through charitable donations. Expenses are allocable to research grants, pilot studies, and associated scientific program support. Activity directly furthers FAR's scientific and educational purposes by advancing basic and translational research related to adenosine biology. Funding early stage research reduces barriers to discovery, promotes dissemination of scientific knowledge, and accelerates progress toward therapies that benefit public health. |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 1 | ACCORD (Adenosine Cancer Collaborative for Oncology Research and Discovery). 10 percent of total activity and 5-8 percent of expenses. FAR convenes and supports ACCORD, a structured scientific collaboration focused on the role of adenosine signaling in cancer biology and treatment. ACCORD facilitates coordinated data review, prioritization of research questions and alignment of preclinical research efforts across participating investigators. The activity includes invited academic researchers, clinicians and scientific advisors. ACCORD activities are conducted through virtual meetings and periodic in-person scientific convenings hosted at partner academic or research institutions. ACCORD is funded through charitable donations. Expenses are primarily for meeting coordination, scientific review support, and limited pilot study funding. By fostering collaboration and coordination among researchers, ACCORD enhances scientific efficiency, reduces duplication of effort, and promotes the generation and dissemination of new scientific knowledge related to cancer biology and treatment. |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 2 | Scientific Advisory and Educational Convenings. 10 percent of total activity and 5-7 percent of expenses. FAR organizes scientific workshops, advisory meetings, and structured educational convenings to review emerging research, define research priorities and educate stakeholders on advances in adenosine biology. Convenings are focused on scientific exchange and strategic research planning. Activities include participation from volunteer scientific advisors, academic researchers, and clinicians. FAR's Scientific Advisory Council will participate on an unpaid, volunteer basis. Activities are conducted through virtual platforms and occasional in-person meetings hosted at academic or nonprofit venues. Funded through charitable donations. These activities further FAR's educational and scientific mission by promoting knowledge sharing, supporting informed research decision-making and advancing understanding of adenosine-related biology and disease mechanisms. |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 3 | Governance, Compliance, and Organizational Operations. 10 percent of total activity and 5-10 percent of expenses. FAR maintains essential governance, compliance and administrative operations, including board management, financial oversight, regulatory filings, donor stewardship and organizational planning. Professional service providers (legal, accounting, insurance) are engaged as needed. Administrative activities are conducted remotely and through third-party service providers. Funded through charitable donations. Effective governance and compliance ensures FAR operates exclusively for charitable and scientific purposes and maintains accountability to donors and the public. |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt | 0 | 42500 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt | 1 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt | 2 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt | 3 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt | 0 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt | 1 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt | 2 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt | 3 | 3155 |
| IRS990EZ/ProhibitedTaxShelterTransInd | 0 | 0 |
| IRS990EZ/RelatedOrganizationCtrlEntInd | 0 | 0 |
| IRS990EZ/SalariesOtherCompEmplBnftAmt | 0 | 0 |
| IRS990EZ/SaleOfAssetsGrossAmt | 0 | 0 |
| IRS990EZ/SchoolOperatingInd | 0 | 0 |
| IRS990EZ/SpecialEventsDirectExpensesAmt | 0 | 0 |
| IRS990EZ/SpecialEventsNetIncomeLossAmt | 0 | 0 |
| IRS990EZ/StatesWhereCopyOfReturnIsFldCd | 0 | VA |
| IRS990EZ/SubjectToProxyTaxInd | 0 | 0 |
| IRS990EZ/SumOfTotalLiabilitiesGrp/BOYAmt | 0 | 0 |
| IRS990EZ/SumOfTotalLiabilitiesGrp/EOYAmt | 0 | 0 |
| IRS990EZ/TanningServicesProvidedInd | 0 | 0 |
| IRS990EZ/TaxImposedOnOrganizationMgrAmt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4911Amt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4912Amt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4955Amt | 0 | 0 |
| IRS990EZ/TaxReimbursedByOrganizationAmt | 0 | 0 |
| IRS990EZ/TotalExpensesAmt | 0 | 45655 |
| IRS990EZ/TotalProgramServiceExpensesAmt | 0 | 3155 |
| IRS990EZ/TotalRevenueAmt | 0 | 75000 |
| IRS990EZ/TransactionWithControlEntInd | 0 | 0 |
| IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd | 0 | 0 |
| IRS990EZ/TypeOfOrganizationCorpInd | 0 | X |
| IRS990ScheduleA/First5Years170Ind | 0 | X |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt | 0 | 75000 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt | 0 | 75000 |
| IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/CurrentTaxYearAmt | 0 | 0 |
| IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/TotalAmt | 0 | 0 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearAmt | 0 | 0 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt | 0 | 0 |
| IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearAmt | 0 | 0 |
| IRS990ScheduleA/OtherIncome170Grp/TotalAmt | 0 | 0 |
| IRS990ScheduleA/PublicOrganization170Ind | 0 | X |
| IRS990ScheduleA/PublicSupportTotal170Amt | 0 | 75000 |
| IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/CurrentTaxYearAmt | 0 | 0 |
| IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/TotalAmt | 0 | 0 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt | 0 | 75000 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt | 0 | 0 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 0 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt | 0 | 0 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt | 0 | 0 |
| IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt | 0 | 75000 |
| IRS990ScheduleA/TotalSupportAmt | 0 | 75000 |
| IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/CurrentTaxYearAmt | 0 | 0 |
| IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/TotalAmt | 0 | 0 |
| IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorNum | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine2 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt | 0 | RESTRICTED |
| ReturnHeader/BuildTS | 0 | 2025-03-06 01:10:19Z |
| ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd | 0 | 1 |
| ReturnHeader/BusinessOfficerGrp/PersonNm | 0 | Uday Gupta |
| ReturnHeader/BusinessOfficerGrp/PersonTitleTxt | 0 | President & Treasurer |
| ReturnHeader/BusinessOfficerGrp/PhoneNum | 0 | 4342423945 |
| ReturnHeader/BusinessOfficerGrp/SignatureDt | 0 | 2026-05-18 |
| ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt | 0 | Foundation for Adenosine Research |
| ReturnHeader/Filer/BusinessNameControlTxt | 0 | FOUN |
| ReturnHeader/Filer/EIN | 0 | 394648664 |
| ReturnHeader/Filer/PhoneNum | 0 | 4342260683 |
| ReturnHeader/Filer/USAddress/AddressLine1Txt | 0 | 1180 Seminole Trail Ste 495 |
| ReturnHeader/Filer/USAddress/CityNm | 0 | Charlottesville |
| ReturnHeader/Filer/USAddress/StateAbbreviationCd | 0 | VA |
| ReturnHeader/Filer/USAddress/ZIPCd | 0 | 22901 |
| ReturnHeader/PreparerFirmGrp/PreparerFirmEIN | 0 | 833544660 |
| ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt | 0 | Shuru Law LLC |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt | 0 | 3334 Turnberry Circle |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm | 0 | Charlottesville |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd | 0 | VA |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd | 0 | 22911 |
| ReturnHeader/PreparerPersonGrp/PhoneNum | 0 | 4342260683 |
| ReturnHeader/PreparerPersonGrp/PreparationDt | 0 | 2026-05-15 |
| ReturnHeader/PreparerPersonGrp/PreparerPersonNm | 0 | Rahul Keshap |
| ReturnHeader/PreparerPersonGrp/SelfEmployedInd | 0 | X |
| ReturnHeader/ReturnTs | 0 | 2026-05-18T16:39:25-07:00 |
| ReturnHeader/ReturnTypeCd | 0 | 990EZ |
| ReturnHeader/TaxPeriodBeginDt | 0 | 2025-10-01 |
| ReturnHeader/TaxPeriodEndDt | 0 | 2025-12-31 |
| ReturnHeader/TaxYr | 0 | 2025 |
Document Assets
No mirrored PDF or thumbnail assets are attached yet.